Female Initiated HIV Prevention Technology

Female Initiated HIV Prevention Technology 7/24/2007
International AIDS Society and Australasian Society for HIV Medicine, Sydney, Australia

Subscribe to Podcasts from IAS 2007

Kaiser Daily Reports on Women and Prevention

For more information on this session, please see the conference Programme-at-a-Glance page.

Full version:

Video

Podcast

Transcript

Speakers for this session:

Co-Chairs

Roberta Black, Ph.D.
Topical Microbicide Team Leader
NIAID's Division of AIDS
United States
Kenneth Hugh Mayer, M.D.
Professor and Director
Brown University AIDS Program (BRUNAP)
United States

Video

Factors Contributing to Diaphragm Size Change Among Enrolled Women at the Durban Site in a Phase III HIV Prevention Clinical Trial

Sharlene Mandalyn Govender

Medical Research Council, HIV Prevention Research Unit

South Africa

Video |

Slides |

Abstract

Diaphragm and Gel Adherence in a Safety Trial in Harare, Zimbabwe

Ariane van der Straten, M.P.H., Ph.D.

Associate Research Scientist
Women’s Global Health Imperative, Dept. of OBGYN, University of California San Francisco

United States

Video |

Abstract

Genital Tract Abnormalities Among Female Sex Workers Who Douche with Lemon/Lime Juice in Northern Nigeria

Atiene Sagay, M.B.B.S., F.W.A.C.S., M.R.C.O.G.

Associate Professor

Dept. of OBGYN, University of Jos/Jos University Teaching Hospital

Nigeria

Video |

Slides |

Abstract

Achieving a 95% Cohort Retention Rate in a Phase III Trial of the Diaphragm and Gel in Southern Africa

Constancia Watadzaushe

Field Coordinator, Project Coordinator
UZ-UCSF Collaborative Programme in Women's Health

Zimbabwe

Video |

Slides |

Abstract

Female-Controlled HIV Prevention Methods in Zimbabwe: How “Involved” Are the Primary Male Partners?

Elizabeth Montgomery, M.P.H.

Women’s Global Health Imperative, Dept. of OBGYN, University of California San Francisco

United States

Video |

Slides |

Abstract

SPL7013 Gel (VivaGel(TM)), a Topical Microbicide in Development for Prevention of HIV and Genital Herpes, Shown to be Well Tolerated and Comparable with Placebo After Seven Days Administration in Healthy Males

Jeremy Paull, B.Sc.(Hons), Ph.D.

Vice President

Development and Regulatory Affairs, Starpharma Pty Ltd

Australia

Video |

Slides |

Abstract

EMAIL ALERTS
Sign up for email alerts and stay informed about upcoming HealthCasts, and the latest health policy issues, news and events.

FAQs

More...

CONTACT US
Contact us by email with any comments, problems, suggestions.
Call the kaisernetwork.org Help Desk at 202-347-5270.

...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ......